The content on this site is intended for healthcare professionals only
Dr Steven O'Day speaks to ecancer about the phase 2 IMPRIME 1 study looking at the combination of pembrolizumab and a novel innate immune activator, Imprime PGG, in second-line, metastatic triple negative breast cancer (mTNBC).
He explains that Imprime PGG is a Beta Glucan agonist which is an innate activator of the immune system and by using this in addition to pembrolizumab the hope was that it would lead to a more robust immune response.
Dr O'Day reports that the results showed significant improvement on historical single agent activity, including a disease control rate beyond 6 months of 25% and a median survival of 16.4%.
ASCO 2024: Lung cancer highlights
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
ASCO 2024: Lung cancer roundup
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
OncoAlert round up July 28th to August 3rd, 2023
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer
ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer
